According to Future Market Insights, the global Dystrophic Epidermolysis Bullosa Management Market will increase at a compound annual growth rate (CAGR) of 5.7% between 2023 and 2033, reaching US$ 787.8 million by 2033. With increased research to cure this illness, the global market for dystrophic epidermolysis bullosa treatment is predicted to grow significantly throughout the forecast period.
Children with RDEB are more likely to develop malignant melanoma, while adults with EB simplex are more likely to develop basal cell carcinoma. The market for patient-centered approaches to treating EB is projected to expand further. Healthcare providers utilise preventative measures, nutritional assistance, and wound care therapies to tailor a plan to each unique patient. Assessment of skin lesions and general health tools are predicted to expand in addition to monitoring and updating the patient’s treatment plan.
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16490
The outcome of antibiotic treatment is determined by the infectious condition of the wound as well as the outcome of an antibiogram. Dermatologists will be able to construct individualised care plans for individuals with EB as a result of the recommended strategies. Based on the data provided by the suggested monitoring tools, the proposed monitoring instruments can be utilised to continuously update the patient’s treatment plan as well as the national recommendations for the management of EB. Furthermore, as part of the next-generation sequencing process, full exome sequences or focused panels may be available. Targeted panels will provide low cost and short turnaround time by evaluating commonly identified genes with 94.3% efficiency and 75-98 sensitivity.
Key Takeaways from the Market Study:
- By 2023, global Dystrophic Epidermolysis Bullosa Management sales are expected to reach US$ 452.37 Million.
- Antibiotics for Dystrophic Epidermolysis Bullosa Management are expected to grow 32% market share between 2023 and 2033.
- Hospital pharmacies for the Dystrophic Epidermolysis Bullosa Management market are projected to grow at a CAGR of 3.4% from 2023 to 2033.
- A market share of 23% is forecasted for the North American Dystrophic Epidermolysis Bullosa Management market.
- European markets are projected to grow at a CAGR of 2.6% during the forecast period.
“The development of stem cell therapy, approval of new topical and oral medicines, and development of diagnostic devices will support the growth of Dystrophic Epidermolysis Bullosa Management market.” comments a Future Market Insights analyst.
Dystrophic Epidermolysis Bullosa Management Market Report Available At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-16490
Competitive Landscape:
Diagnostic techniques are increasingly being developed and researched in parallel as they advance. Several companies will likely expand their product lines, acquire other firms, or merge in the near future as new techniques and treatment emerge.
- Abeona Therapeutics Inc. announced the completion of the final 6-month follow-up visit of its primary Phase 3 VIITAL trial of EB-101, the company’s targeted cell therapy investigation for dystrophic epidermolysis bullosa (RDEB). In order to lock the database within two to three weeks after the last patient’s final visit, Abeona has been verifying and preparing the data in real-time. As a result of the VIITAL study, Abeona intends to seek approval from the U.S. Food and Drug Administration (FDA) for EB-101 for the treatment of RDEB patients.
- Researchers from Relief Therapeutics will test APR-TD011 on the effects of bacterial colonization on epidermolysis bullosa (EB) wounds in a pilot study. A chemical with strong antimicrobial properties, hypochlorous acid, is the active ingredient in the treatment. Buying Nexodyn helps cleanse and moisturize cuts, burns, and abrasions as well as acute wounds. In a trial that has been initiated by the investigator (NCT05533866), 15 patients with junctional EB or dystrophic EB and wounds infected with Staphylococcus aureus and/or Pseudomonas aeruginosa bacteria will be enrolled soon.
Key players in the Dystrophic Epidermolysis Bullosa Management Market:
Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, Wings Therapeutics, InMed Pharmaceuticals, Inc., Regenerx Biopharmaceuticals Inc., Holostem Terapie Avanzate S.r.l
More insights available:
In North America and Europe, where there is a greater prevalence of the condition and higher levels of healthcare spending, there are more treatment options available. These options include wound care management, pain management, and gene therapy. The US Food and Drug Administration (FDA) has approved several products for Dystrophic Epidermolysis Bullosa Treatment, including a topical gel that helps to manage blistering and wound healing.
Request Tailored Insights to Outperform in the Dystrophic Epidermolysis Bullosa Management Market: https://www.futuremarketinsights.com/customization-available/rep-gb-16490
Key Segments Profiled in the Dystrophic Epidermolysis Bullosa Management Industry Survey:
By Disease Type:
- Dominant Dystrophic Epidermolysis Bullosa (DDEB)
- Recessive Dystrophic Epidermolysis Bullosa (RDEB)
By Drug Class:
- Antibiotics
- Corticosteroids
- Opioid Analgesics
- Anticonvulsant
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs